Rosacea - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 71 pages report, published by Global Markets Direct

Keywords : Rosacea Therapeutic Products under Development, Key Players in Rosacea Therapeutics, Rosacea Pipeline Overview, Rosacea Pipeline, Rosacea Pipeline Assessment

Report ThumbnailSeptember-2013
Rosacea - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Rosacea - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rosacea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rosacea. Rosacea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rosacea.
- A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rosacea pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Rosacea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Rosacea, H2 2013 8
  • Products under Development for Rosacea - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Late Stage Products, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Early Clinical Stage Products, H2 2013 14
  • Discovery and Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 29
  • Assessment by Route of Administration, H2 2013 30
  • Assessment by Stage and Route of Administration, H2 2013 31
  • Assessment by Molecule Type, H2 2013 32
  • Assessment by Stage and Molecule Type, H2 2013 33
  • List of Tables
  • Number of Products Under Development for Rosacea, H2 2013 8
  • Products under Development for Rosacea - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 11
  • Comparative Analysis by Late Stage Development, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Products under Investigation by Universities/Institutes, H2 2013 17
  • Allergan, Inc., H2 2013 18
  • Merck & Co., Inc., H2 2013 19
  • Novartis AG, H2 2013 20
  • Galderma S.A., H2 2013 21
  • Paratek Pharmaceuticals, Inc., H2 2013 22
  • Celgene Corporation, H2 2013 23
  • Paloma Pharmaceuticals, Inc., H2 2013 24
  • Foamix Ltd., H2 2013 25
  • Gene Signal International SA., H2 2013 26
  • Cutanea Life Sciences, H2 2013 27
  • Advancell, H2 2013 28
  • Assessment by Monotherapy Products, H2 2013 29
  • Assessment by Stage and Route of Administration, H2 2013 31
  • Assessment by Stage and Molecule Type, H2 2013 33
  • Rosacea Therapeutics - Drug Profile Updates 55
  • Rosacea Therapeutics - Discontinued Products 63
  • Rosacea Therapeutics - Dormant Products 64
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Rosacea Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Rosacea 8
  • Rosacea Therapeutics under Development by Companies 10
  • Late Stage Products 12
  • Comparative Analysis 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Early Clinical Stage Products 14
  • Comparative Analysis 14
  • Discovery and Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Rosacea Therapeutics - Products under Development by Companies 16
  • Rosacea Therapeutics - Products under Investigation by Universities/Institutes 17
  • Companies Involved in Rosacea Therapeutics Development 18
  • Allergan, Inc. 18
  • Merck & Co., Inc. 19
  • Novartis AG 20
  • Galderma S.A. 21
  • Paratek Pharmaceuticals, Inc. 22
  • Celgene Corporation 23
  • Paloma Pharmaceuticals, Inc. 24
  • Foamix Ltd. 25
  • Gene Signal International SA. 26
  • Cutanea Life Sciences 27
  • Advancell 28
  • Rosacea - Therapeutics Assessment 29
  • Assessment by Monotherapy Products 29
  • Assessment by Route of Administration 30
  • Assessment by Molecule Type 32
  • Drug Profiles 34
  • apremilast - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • omiganan pentahydrochloride - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • laropiprant - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • aganirsen - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • P-529 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • minocycline - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • sarecycline hydrochloride - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • BFH-772 - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • oxymetazoline hydrochloride - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • DLX-1008 - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • ivermectin - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • benzoyl peroxide - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • DER-45EV - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • SIG-990 - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • ANs-29 - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • PDI-320 - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • Rosacea Therapeutics - Drug Profile Updates 55
  • Rosacea Therapeutics - Discontinued Products 63
  • Rosacea Therapeutics - Dormant Products 64
  • Rosacea - Product Development Milestones 65
  • Featured News & Press Releases 65
  • Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 65
  • Feb 27, 2013: Galderma Announces Availability Of Apprilon In Canada For Treatment Of Rosacea 65
  • Sep 12, 2011: Foamix To Present Update On Topical Minocycline Foam At UBS 2011 Global Life Sciences Conference 66
  • Aug 15, 2011: Argyle Therapeutics Receives Phase II SBIR Grant To Develop SIG990 66
  • May 01, 2011: Argyle Presents Preclinical Data On SIG990 At 2011 Society For Information Display Conference 66
  • Apr 19, 2011: Vicept Announces Positive Results From Second Phase II Study Of V-101 For Treatment Of Type I Rosacea 66
  • Jan 18, 2011: Foamix Announces Enrollment In Phase II Clinical Trial Of Topical Minocycline Foam For Rosacea 67
  • Jan 10, 2011: Vicept Reports Positive Phase II Data Of V-101 In Type I Rosacea 67
  • Nov 19, 2010: Galderma Announces Results Of Rosacea Trial With Oracea 68
  • Aug 05, 2010: Vicept Therapeutics Announces Positive Clinical Study Results Of V-101 For The Treatment Of The Erythema Of Rosacea 69
  • Appendix 70
  • Methodology 70
  • Coverage 70
  • Secondary Research 70
  • Primary Research 70
  • Expert Panel Validation 70
  • Contact Us 71
  • Disclaimer 71

Please select a license type

Share

Related Products

Global Markets DirectRosacea - Pipeline Review, H2 2013Product ThumbnailRosacea - Pipeline Review, H2 2013, Industry ReportProduct #: 113291
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved